Edition:
India

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Capital Market

1.08USD
16 Nov 2018
Change (% chg)

$-0.05 (-4.42%)
Prev Close
$1.13
Open
$1.12
Day's High
$1.12
Day's Low
$1.08
Volume
25,920
Avg. Vol
327,213
52-wk High
$12.80
52-wk Low
$0.81

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)
No analyst recommendations are available for .

Overall

Beta: 2.17
Market Cap(Mil.): $28.03
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

The U.S. Food and Drug Administration declined to approve Pain Therapeutics Inc's abuse-deterrent opioid treatment Remoxy for the fourth time, sending the company's shares down 35 percent to a record low.

06 Aug 2018

UPDATE 1-U.S. FDA declines to approve Pain Therapeutics' abuse-deterrent opioid drug

Aug 6 Pain Therapeutics said on Monday that the U.S. Food and Drug Administration declined to approve its opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk.

06 Aug 2018

U.S. FDA declines to approve Pain Therapeutics' opioid drug

Aug 6 Pain Therapeutics' said on Monday that the U.S. Food and Drug Administration declined to approve the company's opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk.

06 Aug 2018

Earnings vs. Estimates